Pacific Biosciences Financials - Benzinga

Pacific Biosciences of California Inc

PACBNASDAQ

Trade with Public

Trade with Public

$1.58

À la clôture: Sep 25, 5:00 PM EST

$1.56

-0.02-1.27%

Après les heures: 7:57 PM EST

Aperçu Actualités Prévisions de résultats Événements Objectifs de coursDonnées financièresSentiment Actionnariat Comparer Options Rapport sur les stocks

Pacific Biosciences Financials

Pacific Biosciences (PACB) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Pacific Biosciences Lowers FY2026 Sales Guidance from $165.000M-$175.000M to $155.000M-$165.000M vs $166.790M Est

Pacific Biosciences (NASDAQ:PACB) lowers FY2026 sales outlook from $165.000 million-$175.000 million to $155.000 million-$165.000 million vs $166.790 million estimate.

Benzinga Newsdesk

PRO
Pacific Biosciences Q2 Adj. EPS $(0.14) Misses $(0.13) Estimate, Sales $39.007M Miss $40.067M Estimate

Pacific Biosciences (NASDAQ:PACB) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.13) by 7.69 percent. This is a 7.69 percent decrease over losses of $(0.13) per share

Benzinga Newsdesk

PRO
Pacific Biosciences Sees FY2026 Sales $165.000M-$175.000M vs $173.371M Est

Pacific Biosciences (NASDAQ:PACB) sees FY2026 sales of $165.000 million-$175.000 million vs $173.371 million analyst estimate.

Benzinga Newsdesk

PRO
Pacific Biosciences Q1 Adj. EPS $(0.12) Beats $(0.14) Estimate, Sales $37.178M Miss $39.986M Estimate

Pacific Biosciences (NASDAQ:PACB) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.14) by 7.69 percent. This is a 20 percent increase over losses of $(0.15) per share from

Benzinga Newsdesk

Insights into Pacific Biosciences Q4 Earnings

Benzinga Insights

PRO
Pacific Biosciences Q4 Adj. EPS $(0.12) Beats $(0.15) Estimate, Sales $44.645M Beat $42.530M Estimate

Pacific Biosciences (NASDAQ:PACB) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.15) by 18.37 percent. This is a 40 percent increase over losses of $(0.20) per share from

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved